TG Therapeutics reports Q4 2023 BRIUMVI net revenue $39.9M; 2024 target $220-260M

TG THERAPEUTICS, INC.

2023-FY EPS reported $0.09 revenue$233,662,000

BRIUMVI U.S. net revenue $39.9M in Q4 2023, $88.8M for full year 2023.
Net loss of $14.4M in Q4; net income of $12.7M for full year 2023.
Year-end cash $217.5M; 2024 BRIUMVI net revenue target $220-260M; operating expense ~$250M.
License revenue $141.7M in 2023 driven by $140M Neuraxpharm payment for ex-U.S. rights.
Pipeline: subcutaneous BRIUMVI, azer-cel CAR T in autoimmune disease to start trials in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TG THERAPEUTICS, INC. updated its the fourth quarter and year ended December 31, 2023 guidance (raised).

Period: the fourth quarter and year ended December 31, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On February 28, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three and twelve months ended December 31, 2023.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

TG THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-005802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.